Boehringer Ingelheim Announces Enrollment Is Complete For The ... - Medical News Today (press release)
The RE-LY trial is comparing two blinded doses of oral dabigatran etexilate with warfarin sodium (target INR 2.0-3.0) in patients with non-valvular atrial ...